Free Trial

→ Banks aren’t ready for this altcoin—are you? (From Crypto 101 Media) (Ad)

15 Stocks That Insiders Won't Stop Buying - 14 of 15

Slide 14

Rezolute (NASDAQ:RZLT)

Dollar Amount of Shares Purchased: $4,171,890.31
Number of Insider Purchases in the Last 180 Days: 8
Volume of Shares Purchased: 1,280,405
Who Bought Shares: Brian Kenneth Roberts (Insider), Daron Evans (CFO), Nerissa Kreher (Director), Nevan C Elam (CEO), Wladimir Hogenhuis (Director) and Young-Jin Kim (Director)

Insider Trades by Quarter for Rezolute (NASDAQ:RZLT)

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. More

Slide 14

From Our Partners

web analytics

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

Sign In
Create Account

Your Email Address:

Your Password:

Log In

or

Sign in with Google

Forgot your password?

Your Email Address:

Choose a Password:

or

Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.